Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:FTSV Forty Seven (FTSV) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Forty Seven Stock (NASDAQ:FTSV) 30 days 90 days 365 days Advanced Chart Ad Behind the Markets“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Take these 4 steps to protect your retirement here >>> Get Forty Seven alerts:Sign Up Key Stats Today's Range$95.51▼$95.5150-Day Range$95.51▼$95.5152-Week Range$5.53▼$95.51VolumeN/AAverage Volume1.61 million shsMarket Capitalization$4.60 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewForty Seven Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody. Forty Seven Inc. has a collaboration agreement with Genentech to include third clinical trial in non-Hodgkin's lymphoma. The company was formerly known as CD47 Sciences, Inc. Forty Seven Inc. was incorporated in 2014 and is headquartered in Menlo Park, California.Read More… “Buffett Indicator” Predicts 62% Stock Market Crash (Ad)The last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Take these 4 steps to protect your retirement here >>> Receive FTSV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Forty Seven and its competitors with MarketBeat's FREE daily newsletter. Email Address FTSV Stock News HeadlinesJanus Henderson Forty DOctober 25, 2024 | morningstar.comKareem Hunt's 2 TDs Lead Chiefs Over 49ers 14-6 at HalfOctober 22, 2024 | msn.com625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull run is over. But if history has taught us anything, it’s that this is only the beginning.October 30, 2024 | Crypto Swap Profits (Ad)NFL Week 7 Preview: 49ers vs. Chiefs Key Players to Watch, Stats, TV & Live Stream InfoOctober 21, 2024 | sfgate.comJanus Henderson Forty TSeptember 5, 2024 | morningstar.comJanus Henderson Forty SSeptember 1, 2024 | morningstar.comFazende: Five takes from Saints loss to 49ersAugust 19, 2024 | msn.comFrank Selvy, 91, Dies; Scored 100 Points in a College Basketball GameAugust 13, 2024 | nytimes.comSee More Headlines FTSV Stock Analysis - Frequently Asked Questions How were Forty Seven's earnings last quarter? Forty Seven Inc (NASDAQ:FTSV) issued its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.38) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.38). The firm earned $15.68 million during the quarter, compared to analyst estimates of $15.80 million. When did Forty Seven IPO? Forty Seven (FTSV) raised $100 million in an IPO on Thursday, June 28th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity, BTIG and Oppenheimer were co-managers. What other stocks do shareholders of Forty Seven own? Based on aggregate information from My MarketBeat watchlists, some other companies that Forty Seven investors own include Gilead Sciences (GILD), TG Therapeutics (TGTX), Clovis Oncology (CLVS), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Abbott Laboratories (ABT) and ACADIA Pharmaceuticals (ACAD). Company Calendar Last Earnings11/12/2019Today10/29/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:FTSV CUSIPN/A CIKN/A Webwww.fortyseveninc.com Phone650-352-4150FaxN/AEmployees57Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-87,620,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-50.38% Return on Assets-44.35% Debt Debt-to-Equity RatioN/A Current Ratio14.81 Quick Ratio14.81 Sales & Book Value Annual Sales$15.68 million Price / Sales293.33 Cash FlowN/A Price / Cash FlowN/A Book Value$7.52 per share Price / Book12.70Miscellaneous Outstanding Shares48,156,000Free FloatN/AMarket Cap$4.60 billion OptionableNot Optionable Beta0.40 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report This page (NASDAQ:FTSV) was last updated on 10/30/2024 by MarketBeat.com Staff From Our Partners625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredWho are Nvidia’s New Silent Partners?Nvidia knows it can’t stand still as AI continues to grow at an exponential rate. That’s why CEO Jensen Hua...Weiss Ratings | SponsoredThis biotech's ONE drug could change medicine as we know itThis Clinical-stage Biotech Company is Taking a Revolutionary Approach to Eradicating Many Respiratory Viruses...Smallcaps Daily | SponsoredA new way to play the AI boom (act before November 19)There's a new way to play the $15 trillion AI boom. And it's so simple - you can do it right now with as li...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredThe Death Knell for U.S. StocksThey are among the 31 billionaires dumping their stocks at a record pace. Fortune calls this phenomenon "Th...InvestorPlace | SponsoredInvest in the company that won over the DragonsThe pioneer in smart-doorbell technology, RING, pitched their business on the hit show Shark Tank at a valuati...RYSE | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Forty Seven Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Forty Seven With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.